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A fusion protein comprising a cell penetrating and immunostimulatory peptide corresponding to residues 32 to 51
of the Limulus polyphemus protein linked to human papillomavirus (HPV)-16 E7 antigen (LALF32-51-E7) was expressed
in E. coli BL21 (DE3) cells. The recombinant protein in E. coli accounted for approximately 18% of the total cellular
protein and purified with a single affinity chromatographic step. Yields of approximately 38 mg purified LALF32-51-E7
per liter of induced culture was obtained with an overall 52% recovery and constitutes a promising setting for the
future production and scaling-up. Purified protein was characterized as soluble aggregates with molecular weight
larger than 670 kDa, which is considered an important property to increase the immunogenicity of an antigen
preparation. The recombinant fusion protein LALF32-51-E7 will be a promising vaccine candidate for the treatment of
HPV-16 related malignancies.
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Cervical cancer represents the second most frequent
cancer in women (zur Hausen 2009). Today it is very
well established that so-called high-risk human papillo-
mavirus (HPV) infections, particularly those related to
HPV-16, cause cervical cancer (zur Hausen 2002). The
availability of preventive vaccines against HPVs represents
a milestone in the prevention of this infection (Harper
et al. 2006), but no effective therapeutic vaccine or im-
munological treatment exists for individuals already
infected or for the 470,000 women that develop high-
grade dysplasia, carcinoma in situ, and cervical cancer
each year.
The oncogenic potential of HPV-16 is mainly ascribed to
the viral oncoprotein E7, which has been shown to interact
with a variety of cellular proteins (Munger et al. 2001).
Moreover, being expressed in all the cervical tumors and in
precancerous lesions, the E7 protein represents a specific
target for immunotherapy (zur Hausen 2002).* Correspondence: isis.torrens@cigb.edu.cu
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in any medium, provided the original work is pWe designed a fusion protein comprising a cell pene-
trating and immunostimulatory peptide corresponding
to residues 32 to 51 of the Limulus polyphemus protein
(LALF32-51) linked to HPV-16 E7 antigen (LALF32-51-E7)
and selected E. coli as protein expression systems by its
relative simplicity, its inexpensive and fast high-density
cultivation, the well known genetics and the large num-
ber of compatible tools available for biotechnology (Jana
and Deb 2005).
In a previous paper we describes some results related the
biological properties of this fusion protein, a promissory
vaccine candidate for the treatment of HPV-16-related ma-
lignancies (Granadillo et al. 2011). Here we describe the ex-
pression and purification and some results concerning the
characterization of this recombinant fusion protein. We
demonstrated that LALF32-51-E7 is highly expressed in E.
coli BL21 (DE3) and easily purified with a single chromato-
graphic step with a high purity. Non-optimized yields
obtained by us are in order of 38 mg/l of bacterial culture,
a very promising setting for the future production and scal-
ing-up. We also show that the protein is obtained in a
highly aggregated form, a property that is considered veryis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Figure 1 Expression and purification of the fusion protein
LALF32-51-E7. (A) SDS-PAGE (15%). (B)Western Blot using anti-HPV-16
E7 monoclonal antibody: initial crude extract of E. coli proteins
containing the expressed (about 18%) fusion protein LALF32-51-E7
(lane 1); soluble fraction after cell disruption (lane 2); insoluble fraction
after cell disruption (lane 3); soluble fraction after treatment with 6 MResults
Bacterial expression and purification of LALF32-51-E7
fusion protein
The DNA sequence of kanamycin resistance gene (KanR)
was amplified by PCR from the corresponding gene of a
reliable plasmid template, purified and cloned into
pPEPE7M-7 vector (Granadillo et al. 2011), which expresses
the 134 amino acid LALF32-51-E7 fusion protein. After cor-
roborating that the KanR gene was successfully cloned,
BL21 (DE3) cells were transformed with the pPEPE7M-7K
plasmid and induced for expression obtaining approxi-
mately 7 g/l of biomass at the end of the fermentation
process. As shown in Figure 1A, lane 1, LALF32-51-E7
accounted for approximately 18% of the total cellular pro-
tein and migrated as an approximately 24 kDa protein in
15% sodium dodecyl sulfate polyacrilamide electrophoresis
(SDS-PAGE). The fusion protein was located in the insol-
uble fraction after cell disruption (Figure 1A, lane 3). This
protein was solubilized from bacterial pellet using 6 M urea
(Figure 1A, lane 4) and further purified by immobilized
metal-ion affinity chromatography (IMAC) up to 94% pur-
ity (Figure 1A, lane 9). The fusion protein was recognized
by an anti-HPV-16 E7 mouse monoclonal antibody in
Western blot (Figure 1B). The 300 mM imidazole eluate
contains a major 24 kDa LALF32-51-E7 band and high mo-
lecular weight (MW) aggregates of this same protein, as
shown by Western Blot analysis (Figure 1B, lanes 8 and 9).
Yields of approximately 38 mg purified LALF32-51-E7 per
liter of induced culture was obtained with an overall 52% re-
covery (Table 1). The IMAC-purified fusion protein was fur-
ther analyzed by size exclusion analytic HPLC in Superdex
200 10/300 GL. A major peak eluting in the void volume of
the column and accounting for 100% of the applied protein
was obtained (Figure 1C). According to the used column
calibration standard, this peak appears to contain soluble
aggregates with MW larger than 670 kDa.urea (lane 4); insoluble fraction after treatment with 6 M urea (lane 5);
IMAC purification, initial sample (lane 6); IMAC purification, wash with
10 mM imidazole (lane 7); IMAC purification, elution with 300 mM
imidazole (lane 8); 300 mM imidazole elution fraction after desalting
(lane 9). Molecular mass markers are indicated on the left. (C) Analytical
gel filtration chromatogram of purified LALF32-51-E7 (continuous line).
Dash line is representative of the retention time for (from left to right)
bovine thyroglobulin (670 kDa), bovine gamma globulin (158 kDa),
ovalbumin (44 kDa), myoglobin (17 kDa) and vitamin B-12 (1.35 kDa).Transmission electron microscopy studies
In order to corroborate if the LALF32-51-E7 fusion pro-
tein was expressed as inclusion bodies, ultrastructural
studies were performed. As expected, transmission elec-
tron microscopy study of cells harboring pPEPE7M-7K
indicated that the fusion protein is produced as cytoplas-
mic inclusion bodies (Figure 2A).
To characterize the purified fusion protein, preparations
of LALF32-51-E7 were analyzed by negative staining. The
Figure 2B shows representative electron microscopy
micrograph of the LALF32-51-E7 preparation. The protein
appears as aggregates of different shape and size.Mass spectrometry analysis
According to the gene sequence, LALF32-51-E7 is synthesized
as a protein of 134 amino acids containing a hexa-histidine
tag at the C-terminus, with a theoretical mass value of
15867.85 Da. ESI-MS of reduced and carboamidomethylated
















Initial crude extract 30 5.85 18 31.59 1 100 100
Insoluble fraction after cell
disruption
30 2.33 32 22.37 1.7 71 71
Solubilization 15 3.07 45 20.72 1.4 93 66
IMAC elution 25 0.75 94 17.63 2 85 56
Desalting 35 0.5 94 16.45 1 93 52
a Determined by densitometry.
The protein concentration was determined by Bio-Rad protein assay (Bradford 1976), using bovine serum albumin as the reference standard.
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15736.90 Da in mass (Figure 3A), which is in good agree-
ment with the theoretical value (15736.65 Da) calculated
for the sequence starting from the second amino acid
(alanine, abbreviated A in Figure 4). The major signal
obtained differs in 130.95 mass units with respect to the
expected theoretical mass of entire protein (15867.85 Da),
indicating a full processing of the initiation methionine
from the protein.
To further verify the identity of the molecule, the pro-
tein was enzymatically digested with trypsin, and gener-
ated fragments were analyzed by mass spectrometry.
Identified peptides accounted for 93% of the entire se-
quence of LALF32-51-E7 (Table 2). Undetected peptides
corresponded to fragments with less than 3 amino acids
which are out of the mass range analysis of the mass
spectrometer (400–2000 Th). ESI-MS/MS sequencing of
N- and C-terminal suspected peptides confirm the lack
of the initiation methionine (Figure 3B) and the presence
of the six-His-tag, respectively (Figure 3C).Discussion
In this paper, we describe the expression, purification and
some results related to the characterization of LALF32-51-
E7 fusion protein; a promising vaccine candidate for the
treatment of HPV-16 related malignancies. Antigen design
was based on mutated version of viral HPV-16 E7 antigen
bearing a base substitution of T by G in the triplet encod-
ing cysteine at position 24 (substitution of Cys to Gly) in
order to disrupt their binding to protein Rb (Munger et al.
1989; Barbosa et al. 1990; Jones et al. 1990), in this way re-
ducing possible regulatory objections in the future devel-
opment of a human vaccine candidate. To improve safety,
and since the ampicillin resistance gene (AmpR) is pre-
cluded for use in humans, we introduced the KanR
gene as a selectable marker of our final expression vector
pPEPE7M-7K. The KanR gene is the antibiotic resistance
marker often used while the AmpR is not acceptable
due to concerns with hyper reactivity of some patients to
β lactam antibiotics (Williams et al. 2009).It is well documented that a key aspect influencing on
the expression of heterologous proteins in E. coli cytoplasm
is the selection of host strain (Sorensen and Mortensen
2005). In this sense E. coli BL21 (DE3) is the most com-
mon host and has proven outstanding in standard recom-
binant expression application, is able to grow vigorously in
minimal media but however non-pathogenic and unlikely
to survive in host tissues and cause disease (Chart et al.
2000). In this paper, we show that the fusion protein
LALF32-51-E7 is highly expressed (18%) in E. coli BL21
(DE3). In agreement with our results other researchers
have expressed efficiently recombinant fusion proteins for
therapeutic purposes based on HPV-16 E7 antigen in E.
coli (Chu et al. 2000; Preville et al. 2005; Liu et al. 2008).
In this work we also show that LALF32-51-E7 was easily
purified with a single affinity chromatographic step (up to
94% purity) that can be followed by other polishing ones
(i.e. gel filtration) if manufactured for human vaccine pur-
poses. The non-optimized yields obtained by us are in
order of 38 mg of purified LALF32-51-E7 per liter of
induced culture, a promising figure in terms of production
and scaling-up. This study also reports that the fusion pro-
tein was obtained highly aggregated, a property that could
be convenient to enhance immunogenicity for an antigen
preparation. Other researchers have reported that while
low MW aggregates such as dimers and trimers appear in-
efficient in inducing immune responses, large multimers
whose MW exceeds 100 kDa are efficient inducers of im-
mune responses (Rosenberg 2006). As our aim was to ob-
tain a highly immunogenic E7 preparation, we did not focus
on obtaining aggregates of identical shape and size consider-
ing that particles of different size can be taken up by differ-
ent types of antigen presenting cells, such as dendritic cells,
macrophages and polymorphonuclear leukocytes, sustaining
a more potent immune response (Oyewumi et al. 2010).
In this study we also characterized the LALF32-51-E7 fu-
sion protein by mass spectrometry. LALF32-51-E7 is a 134
amino acids protein with a hexa-histidine tag at the C-
terminus and a theoretical molecular mass of 15867.85 Da.
The mass spectrometry analyses were in good agreement
with the theoretical molecular mass value of the full length
Figure 2 Transmission electron micrographs.
(A) Microphotograph showing at ultrastructural level the presence
of inclusion bodies inside the E. coli transformed cell, corresponding
to the LALF32-51-E7 fusion protein. The bar represents 500 nm.
(B) Electron micrograph of the negatively stained LALF32-51-E7
preparation sample showing aggregates of different shape and size.
The bar represents 200 nm.
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fied the identity of the molecule.
Although the theoretical mass value of LALF32-51-E7 is
approximately 16 kDa, the protein migrated in SDS-PAGE
under reducing conditions as an approximately 24 kDa
protein that is larger in size than predicted. This abnormal
migration pattern has been previously reported for the
HPV-16 E7 protein, and is attributable to their highcontent of acidic amino acid residues (Armstrong and
Roman 1993; Bolhassani et al. 2008).
The E. coli expressed proteins represent a well-studied
and cost-effective means for the production of vaccines.
Our vaccine candidate represents not only a good substrate
for antigen-presenting cell uptake and processing, but also
a cost-effective promising approach for developing a HPV
therapeutic vaccine. A generation of new low-cost HPV
vaccines could represent the only possibility for women liv-
ing in developing countries to gain access to HPV vaccin-
ation programs to prevent or treat pre-cancerous lesions
and cancer.
Conclusions
This is a report of a non-optimized process about the
expression, purification and characterization of a recom-
binant fusion protein that is a cost-effective promising
approach for developing a HPV therapeutic vaccine.
Methods
Fusion protein expression vector
The AmpR gene of the plasmid pPEPE7M-7 (Granadillo
et al. 2011) that containing the recombinant LALF32-51-E7
fusion protein was interrupted by digestion with ScaI and
a DNA fragment containing the KanR gene was cloned in
this plasmid. The KanR gene was PCR amplified from
pUC4K using two primers. The forward primer 5’ CAG
CTG GCC ACG TTG TGT CTC AAA ATC 3’ contains a
PvuII site as well as the reverse primer 5’ CAG CTG TTC
AAC AAA GCC GCC GTC CC 3’. The PCR product was
digested with PvuII, purified and ligated to pPEPE7M-7
which had been cut with ScaI. The KanR gene orientation
was verified by ClaI digestion. Clones resulting in bands of
approximately 3.2 and 1.3 kb have opposite orientation re-
spect to the target gene and clones resulting in bands of
2.5 and 2 kb have the same orientation respect to the tar-
get gene. We selected the clone in which the KanR gene
has opposite orientation respect to the target gene and
was designated pPEPE7M-7K (Figure 4).
Expression and purification of LALF32-51-E7
BL21 (DE3) cells transformed with pPEPE7M-7K were
inoculated in 500 ml of LB medium containing kanamy-
cin (50 μg/ml) and incubated for 6 h at 37°C in a shaker.
This culture were used to inoculate a 5 l fermentor (B.E.
Marubishi, Japan) containing M9 salt medium enriched
with 10 g/l casein hydrolysate, 0.011 g/l CaCl2 · 2H2O,
0.246 g/l MgSO4 · 7H2O, 2 g/l glucose and 0.05 g/l kana-
mycin. After three h, 3 β-indole-acrylic acid was added to
a final concentration of 0.04 g/l and the culture was grown
for another 15 h to obtain as much possible recombinant
protein as insoluble inclusion bodies according to the
standard production protocol for E coli based technology
implemented in our institute. The fermentation parameters
BC
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Figure 3 Mass spectrometry analysis. (A) ESI mass spectra of rcm-LALF32-51-E7. (B) Sequencing by ESI-MS/MS of the peptide of m/z 411.70
corresponding to the N-terminal of LALF32-51-E7. (C) Sequencing by ESI-MS/MS of the peptide of m/z 456.70 corresponding to the C-terminal of
LALF32-51-E7.
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operated in a batch mode.
Cells were harvested by centrifugation at 15 000 g for
20 min at 4°C. Then, 3 g of cellular biomass was resus-
pended in 30 ml of rupture buffer (50 mM NaH2PO4,
300 mM NaCl, pH 8.0) at a ratio of biomass/buffer of
1:10. The biomass was disrupted in French Press (Othake,
Japan) at 1500 bar, with two passes on 4°C. After centrifu-
gation at 15 000 g for 30 min at 4°C, the pellet was recov-
ered and the recombinant protein was totally solubilized
in 6 M urea in carbonate-bicarbonate buffer pH 10.6. Cell
debris was removed by centrifugation at 15 000 g for
30 min at 4°C and the soluble fraction containing the fu-
sion protein, that have a six-histidine C-terminus tail for
purification purposes, was recovered. Due to the recom-
binant protein was totally solubilized in 6 M urea incarbonate-bicarbonate buffer pH 10.6 and not in other
buffers at lowers pH and at different urea concentrations
(data not shown), the purification of the protein was
necessarily conducted in carbonate-bicarbonate buffer
pH 10.6. The soluble fraction was diluted in equal volume
of 1 M NaCl and loaded onto a 22 ml His-SelectW Nickel
Affinity Gel (Sigma, Catalog number P6611) equilibrated
with loading buffer (3 M urea and 0.5 M NaCl in
carbonate-bicarbonate pH 10.6). The column was then
washed with loading buffer containing 10 mM imidazole
and the protein of interest was eluted with 300 mM imid-
azole. The eluted IMAC fraction (25 ml) was further load-
ing onto a HiPrep 26/10 desalting column (GE Healthcare)
equilibrated with 10 mM Tris pH 8.0 renaturation buffer
and following the manufacturer’s instructions. In this chro-
matographic step the protein was refolded because the
Ptrp LALF32-51 HPV16 E7
T4 ter
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Figure 4 Schematic representation of pPEPE7M-7K construction for the expression of the LALF32-51-E7 fusion protein.
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tions containing LALF32-51-E7 protein were pooled after
desalting and then endotoxin removal was performed using
an EndoClean™ Kit from BioVintage. The final protein
preparation contained <0.05 endotoxin units (EU)/μg as
measured by the chromogenic Limulus ameobocyte lysate
assay (Associates of Cape Cod, Inc). Samples in each step
of the process were collected and later analyzed by SDS-Table 2 Observed m/za values of the tryptic peptides
derived from rcm-LALF32-51-E7 and their theoretical






411.70 411.70 2 2-7b
761.44 761.47 1 8-13
480.25 480.26 1 23-25
1396.20 1396.20 4 26-75
706.83 706.83 2 76-86
751.35 751.34 1 87-92
664.34 664.34 2 93-103
882.46 882.45 3 104-127
1124.60 1124.57 2 103-123
416.22 416.23 1 124-127
456.70 456.71 2 128-134c
a Mass to charge ratio.
b N-terminal peptide.
c C-terminal peptide.PAGE and Western blot. The MW of the recombinant
protein was estimated using size exclusion analytic HPLC
(YL9100) in a Superdex 200 10/300 GL column (GE
Healthcare); briefly 200 μL of the purified protein were ap-
plied at a flow rate of 0.5 ml/min in 10 mM Tris (pH 8.0).
MW was estimated using the retention times, in compari-
son with a gel filtration standard preparation (Bio-Rad).SDS-PAGE and Western blot
SDS-PAGE (15%) was performed according to Laemmli
(Laemmli 1970). Protein expression and purity were evalu-
ated by densitometry (TDI-1D manager 2.0 software,
Spain) of SDS-PAGE gels. Proteins were visualized by
Coomasie blue staining. The identity of the protein was
verified by Western blot (Burnette 1981). Briefly, proteins
were separated by SDS-PAGE and transferred to Hybond
C extra nitrocellulose (Amersham Biosciences) in a semi-
dry transfer unit (Bio-Rad). The membrane was blocked
with 5% skimmed milk in PBS (140 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4, pH 7.4)/0.1%
Tween 20 (PBS-T) overnight at 4°C. After three washes
with PBS-T, the membrane was incubated for 2 h at 25°C
with mouse anti-HPV-16 E7 monoclonal antibody (Abcam)
diluted 1:1000 in blocking solution. The membrane was
washed three times with PBS-T and further incubated for
1 h at 25°C with goat anti-mouse IgG antibodies conjugated
with HRP (Sigma) diluted 1:5000 in blocking solution. After
extensively washing with PBS-T, the antibody-reactive
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kit (Amersham Pharmacia Biotech).
Transmission electron microscopy
For ultrastructural studies the samples consisting of pel-
leted cells (2 x 107 cells) from non-transformed or trans-
formed BL21 (DE3) E. coli that express the recombinant
fusion protein were fixed with 3.2% glutaraldehyde, and
post-fixed for 1 h in 2% OsO4. Then it was rinsed with
0.1 M PBS, pH 7.2, and dehydrated in increasing ethanol
concentrations such as 50%, 70%, 80%, 90% and 100%.
The embedding was in Spurr. The blocks were sectioned
with an ultramicrotome (NOVA, LKB), and the ultrathin
sections were placed on 400-mesh cooper grids. The
ultrathin sections were stained with uranyl acetate and
lead citrate and then examined in a JEOL-JEM 2000 EX
electron microscope (JEOL, Japan).
For the negative staining studies, a drop of purified
LALF32-51-E7 fusion protein was placed on to a 400-mesh
copper grid coated with formvar-carbon film. Following
30 min of sample absorption and washing with water,
grids were stained for 30 s with 2% uranyl acetate. After
staining, grids were dried with Whatman no. 1 filter paper
and allowed to air dry for 15 min. Samples were then
viewed on JEOL-JEM 2000 EX electron microscope.
Reduction and S-carboamidomethylation of cysteines
The LALF32-51-E7 protein (10 nmoles) was dissolved in
100 ml of 6 M guanidium chloride, 500 mM Tris, pH 8.1,
and incubated for 2 h with dithiothreitol (DTT) 50-fold in
excess over cysteines, in a nitrogen atmosphere at 37°C.
Iodoacetamide was added 2-fold over DTT, and the reac-
tion proceeded at 25°C for 30 min in the dark. The
reduced and fully alkylated protein (rcm-LALF32-51-E7)
was desalted by HPLC system (LKB-Phamacia, Sweeden)
in a RP-C4 column (4.6 x 50 mm, Vydac). The elution was
performed with a linear gradient of solvent B (0.05% TFA
in acetonitrile) from 5 to 60% in 30 min at a flow rate of
0.8 ml/min (Solvent A, 0.1% TFA in water). The eluate
was monitored at 226 nm. An aliquot was submitted to
ESI-MS analysis and the rest of the sample was evaporated
under vacuum to dryness before trypsin digestion.
Trypsin digestion
The rcm-LALF32-51-E7 was reconstituted in 0.05%
NH4HCO3 buffer and digested with trypsin (Promega,
USA) at enzyme-to substrate mass ratio 1:50 for 4 h at
37°C.
Mass spectrometry
ESI-MS and MS/MS spectra were acquired using a hybrid
quadrupole orthogonal acceleration tandem mass spec-
trometer QTOF-2™ from Micromass (Manchester, UK)
fitted with a Z-spray nanoflow electrospray ion source.Other measuring conditions and data processing were the
same as reported previously (Gonzalez et al. 2003).
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MW: Molecular weight; SDS-PAGE: Sodium dodecyl sulfate polyacrilamide
electrophoresis.
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